...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Novel synthetic approach to N-aryl-4-(3-pyridyl)thiazol-2-amine and analogues using HMCM-41 as catalyst, and their biological evaluation as human platelet aggregation inhibitors.
【24h】

Novel synthetic approach to N-aryl-4-(3-pyridyl)thiazol-2-amine and analogues using HMCM-41 as catalyst, and their biological evaluation as human platelet aggregation inhibitors.

机译:使用HMCM-41作为催化剂的N-芳基-4-(3-吡啶基)噻唑-2-胺及其类似物的新型合成方法,以及它们作为人血小板聚集抑制剂的生物学评估。

获取原文
获取原文并翻译 | 示例

摘要

A novel synthetic approach to N-aryl-4-(3-pyridyl)thiazol-2-amine and analogues using HMCM-41, a mesoporous aluminosilicate catalyst and their in vitro ADP-induced platelet aggregation inhibitory activity on human blood platelets is described. Among the test compounds N-(2'-flourophenyl)-4-(3-pyridyl)thiazol-2-amine (9e) was found to be the most potent, IC(50)=4.84x10(-7)M.
机译:描述了使用HMCM-41,中孔铝硅酸盐催化剂及其对人血小板的体外ADP诱导的血小板聚集抑制活性的N-芳基-4-(3-吡啶基)噻唑-2-胺及其类似物的新型合成方法。在测试化合物中,发现N-(2'-氟苯基)-4-(3-吡啶基)噻唑-2-胺(9e)最有效,IC(50)= 4.84x10(-7)M。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号